Skip to Content

Press Release

Tiziana Life Sci PLC - Change to ADS ratio

October 30, 2019 at 6:31 AM EDT
RNS Number : 6279R
Tiziana Life Sciences PLC
30 October 2019

Tiziana Life Sciences plc

Change to ADS ratio

London, 30 October 2019 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level I American Depositary Receipt ("ADR") programme.

The former ratio of ten (10) ordinary shares to one (1) American Depositary Share ("ADS") has been changed to five (5) ordinary shares per one (1) ADS effective on 29 October 2019. There will be no change to the underlying ordinary shares.

ADR record date:

21 October 2019

ADR payment date:

28 October 2019

ADR effective date:

29 October 2019







Old Ratio:

1 ADR: 10 ordinary Shares

New Ratio:

1 ADR: 5 ordinary Shares

Underlying ISIN:


Country of incorporation:

United Kingdom


J.P. Morgan Chase Bank, N.A.


J.P. Morgan Chase Bank, London


To effect this change, ADR holders will receive one (1) additional ADR for every one (1) ADR held as of 21 October 2019, the ADR record date. Existing ADRs will continue to be valid and will not have to be exchanged for new ADRs. In connection with this change, the register held by JPMorgan has been closed for issuances and cancellations from the close of business 21 October 2019 and will reopen on 31 October 2019.

For further information, please contact:

JPMorgan Service Centre     ADR Settlements

001 800-990-1135                   001 302-552-0230




Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder

+44 (0)20 7495 2379

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner

+44 (0)20 7213 0883

Shore Capital (Nominated brokers)

Antonio Bossi

+44 (0)20 7408 4050


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit